PEG-Intron: Daptomycin CAPed

Cubist Pharmaceuticals Inc. doesn't know why its first Phase III trial of Cidecin daptomycin in community acquired pneumonia (CAP) failed, but the company has long maintained that the indication isn't important in and of itself. Rather, the company has said that the primary purpose of its CAP trials was to build a safety

Read the full 533 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers